Author:
Sullivan James C.,De Meyer Sandra,Bartels Doug J.,Dierynck Inge,Zhang Eileen Z.,Spanks Joan,Tigges Ann M.,Ghys Anne,Dorrian Jennifer,Adda Nathalie,Martin Emily C.,Beumont Maria,Jacobson Ira M.,Sherman Kenneth E.,Zeuzem Stefan,Picchio Gaston,Kieffer Tara L.
Publisher
Oxford University Press (OUP)
Subject
Infectious Diseases,Microbiology (medical)
Reference17 articles.
1. Discovery and development of telaprevir: an NS3–4A protease inhibitor for treating genotype 1 chronic hepatitis C virus;Kwong;Nat Biotechnol,2011
2. Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3·4A serine protease;Lin;Infect Disord Drug Targets,2006
3. VX-950, a novel hepatitis C virus (HCV) NS3-4A protease inhibitor, exhibits potent antiviral activities in HCV replicon cells;Lin;Antimicrob Agents Chemother,2006
4. Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease;Perni;Antimicrob Agents Chemother,2006
5. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy;Neumann;Science,1998
Cited by
130 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献